CA3206093A1 - Compositions and methods for the treatment of graft versus host disease - Google Patents
Compositions and methods for the treatment of graft versus host disease Download PDFInfo
- Publication number
- CA3206093A1 CA3206093A1 CA3206093A CA3206093A CA3206093A1 CA 3206093 A1 CA3206093 A1 CA 3206093A1 CA 3206093 A CA3206093 A CA 3206093A CA 3206093 A CA3206093 A CA 3206093A CA 3206093 A1 CA3206093 A1 CA 3206093A1
- Authority
- CA
- Canada
- Prior art keywords
- apraglutide
- subject
- administered
- gvhd
- transplant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142905P | 2021-01-28 | 2021-01-28 | |
| US63/142,905 | 2021-01-28 | ||
| US202163248074P | 2021-09-24 | 2021-09-24 | |
| US63/248,074 | 2021-09-24 | ||
| PCT/US2022/014349 WO2022165204A1 (en) | 2021-01-28 | 2022-01-28 | Compositions and methods for the treatment of graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206093A1 true CA3206093A1 (en) | 2022-08-04 |
Family
ID=80461100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206093A Pending CA3206093A1 (en) | 2021-01-28 | 2022-01-28 | Compositions and methods for the treatment of graft versus host disease |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220233645A1 (https=) |
| EP (2) | EP4635509A1 (https=) |
| JP (1) | JP2024507324A (https=) |
| KR (1) | KR20230167019A (https=) |
| AU (1) | AU2022212119A1 (https=) |
| BR (1) | BR112023014978A2 (https=) |
| CA (1) | CA3206093A1 (https=) |
| ES (1) | ES3044110T3 (https=) |
| IL (1) | IL304675A (https=) |
| MX (1) | MX2023008793A (https=) |
| WO (1) | WO2022165204A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025208047A1 (en) * | 2024-03-28 | 2025-10-02 | Vectivbio Ag | Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8421271B2 (en) * | 2009-08-31 | 2013-04-16 | General Electric Company | Apparatus for transferring energy using onboard power electronics and method of manufacturing same |
| EP2314616A1 (en) | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| EP3924369A1 (en) * | 2019-02-11 | 2021-12-22 | OPKO Biologics Ltd. | Long-acting glp-2 analogs |
| KR20230038187A (ko) | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
-
2022
- 2022-01-28 CA CA3206093A patent/CA3206093A1/en active Pending
- 2022-01-28 WO PCT/US2022/014349 patent/WO2022165204A1/en not_active Ceased
- 2022-01-28 ES ES22705498T patent/ES3044110T3/es active Active
- 2022-01-28 EP EP25186217.3A patent/EP4635509A1/en active Pending
- 2022-01-28 US US17/587,311 patent/US20220233645A1/en not_active Abandoned
- 2022-01-28 EP EP22705498.8A patent/EP4284410B1/en active Active
- 2022-01-28 MX MX2023008793A patent/MX2023008793A/es unknown
- 2022-01-28 KR KR1020237029222A patent/KR20230167019A/ko active Pending
- 2022-01-28 BR BR112023014978A patent/BR112023014978A2/pt unknown
- 2022-01-28 US US18/274,622 patent/US20240123036A1/en active Pending
- 2022-01-28 AU AU2022212119A patent/AU2022212119A1/en active Pending
- 2022-01-28 JP JP2023544229A patent/JP2024507324A/ja active Pending
-
2023
- 2023-07-24 IL IL304675A patent/IL304675A/en unknown
- 2023-10-13 US US18/486,390 patent/US20240285730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL304675A (en) | 2023-09-01 |
| JP2024507324A (ja) | 2024-02-19 |
| ES3044110T3 (en) | 2025-11-26 |
| AU2022212119A1 (en) | 2023-08-10 |
| AU2022212119A9 (en) | 2024-05-16 |
| EP4635509A1 (en) | 2025-10-22 |
| BR112023014978A2 (pt) | 2023-11-07 |
| EP4284410A1 (en) | 2023-12-06 |
| EP4284410B1 (en) | 2025-07-02 |
| WO2022165204A1 (en) | 2022-08-04 |
| US20240123036A1 (en) | 2024-04-18 |
| US20220233645A1 (en) | 2022-07-28 |
| US20240285730A1 (en) | 2024-08-29 |
| KR20230167019A (ko) | 2023-12-07 |
| MX2023008793A (es) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| BR112018003212A2 (en) | diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation | |
| CN105722852B (zh) | 用于治疗口腔粘膜炎的新型肽和类似物 | |
| JP2005008534A (ja) | 抗癌剤及び癌の治療方法 | |
| US8435520B2 (en) | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections | |
| US20240285730A1 (en) | Compositions and methods for the treatment of graft versus host disease | |
| WO2012031293A1 (en) | Compositions and methods for the treatment of cancer | |
| MXPA05009741A (es) | Tratamientos antitumorales mejorados. | |
| CN117460523A (zh) | 用于治疗移植物抗宿主病的组合物和方法 | |
| HK40102861B (en) | Apraglutide for use in the treatment of gastrointestinal graft versus host disease | |
| HK40102861A (en) | Apraglutide for use in the treatment of gastrointestinal graft versus host disease | |
| EA051756B1 (ru) | Композиции и способы лечения болезни "трансплантат против хозяина" | |
| WO2025208047A1 (en) | Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease | |
| Giralt et al. | Studies of decitabine with allogeneic progenitor cell transplantation. | |
| US10154989B2 (en) | Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof | |
| Suzuki et al. | A new immunosuppressant, FTY720, in canine kidney transplantation: Effect of single‐drug, induction and combination treatments | |
| CA3106783A1 (en) | Combination therapy for treating cancer | |
| JP2006522060A5 (https=) | ||
| Han et al. | Artesunate synergized dexamethasone in protecting intestinal barrier against acute graft-versus-host disease in a murine model | |
| JP2025525510A (ja) | Ｂｃｌ－２阻害剤を含む癌併用療法 | |
| Raida et al. | Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia | |
| HK1221960B (zh) | 用於治疗口腔粘膜炎的新型肽和类似物 | |
| CA3154497A1 (en) | Combination therapy for treating a hematological malignancy | |
| Martella et al. | A pilot study of a day one and eight every three weeks administration of docetaxel in metastatic cancer patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241230 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241230 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241230 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260128 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |